EVALUATION OF CA125 AS A CIRCULATING TUMOR MARKER FOR OVARIAN CANCER
スポンサーリンク
概要
- 論文の詳細を見る
CA125 usefulness was evaluated using sera from healthy persons, pregnant women, and patients with ovarian, and other tumors.Since serum CA125 levels significantly depended on sex and age in healthy persons, the original cut-off levels were 40 and 25 U/ml in terms of sex and age. Changes in CA125 Ievels within 40 U/ml , were observed during the menstruation cycle. Elevation of CA125 levels was also observed during the first trimester of pregnancy, but these levels fell below 50 U/ml as pregnancy progressed.Immunostaining of the endometrium with OC125 suggested that ovarian function may play an important role in production of CA125 in early pregnancy and menstruating young women. Elevated levels of CA125 were detected in 33/34 (97%) cases with surgically demonstrated ovarian cancer. The clinical usefulness of CA125 for monitoring the course of ovarian cancer was reconfirmed. Practical application of CA125 proved to be useful for the early detection of ovarian cancer and confirmation of the complete disappearance of any tumor.
- 社団法人日本産科婦人科学会の論文
- 1986-06-01
著者
-
Kuzuya Kazuo
愛知県立がんセンター病院 婦人科
-
Kuzuya K
Department Of Gynecology Aichi Caner Center Hospital
-
Kuzuya Kazuo
Department Of Gyneclogy
-
Kuzuya Kazuo
Department Of Gynecology Aichi Cancer Center
-
Kuzuya K
Aichi Cancer Center Hospital Nagoya Jpn
-
Kuzuya Kazuo
Department Of Gynecology Aichi Caner Center Hospital
-
NOZAKI Makoto
Department of Gynecology, Aichi Cancer Center Hospital
-
CHIHARA Tsutomu
Department of Gynecology, Aichi Cancer Center Hospital
-
Nozaki Makoto
Department Of Gynecology Aichi Cancer Center Hospital
-
Chihara Tsutomu
Department Of Gynecology Aichi Cancer Center Hospital
関連論文
- Comparative Case-referent Study of Risk Factors among Hormone-related Female Cancers in Japan
- Smoking and Dietary Risk Factors for Cervical Cancer at Different Age Group in Japan
- Subsite (cervix/endometrium)-specific Risk and Protective Factors in Uterus Cancer
- Salvage treatment with docetaxel for recurrent epithelial ovarian cancer
- Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study
- 3-Hour infusion of single-agent paclitaxel for recurrent ovarian cancer
- Chemoradiotherapy for uterine cancer : current status and perspectives
- EVALUATION OF CA125 AS A CIRCULATING TUMOR MARKER FOR OVARIAN CANCER
- P1-IS-35 Clear cell carcinoma of the ovary : retrospective analysis of Japan Clear Cell Carcinoma Study
- Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin : retrospective analysis
- IS-15 Patients with stage IIIc ovarian clear cell carcinoma upstaged by lymph node metastasis have similar survival to other stage III clear cell carcinoma patients(Group2 Oncology2,International Session)